1. Home
  2. GH vs PIPR Comparison

GH vs PIPR Comparison

Compare GH & PIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GH
  • PIPR
  • Stock Information
  • Founded
  • GH 2011
  • PIPR 1895
  • Country
  • GH United States
  • PIPR United States
  • Employees
  • GH N/A
  • PIPR N/A
  • Industry
  • GH Medical Specialities
  • PIPR Investment Bankers/Brokers/Service
  • Sector
  • GH Health Care
  • PIPR Finance
  • Exchange
  • GH Nasdaq
  • PIPR Nasdaq
  • Market Cap
  • GH 4.3B
  • PIPR 5.2B
  • IPO Year
  • GH 2018
  • PIPR N/A
  • Fundamental
  • Price
  • GH $31.83
  • PIPR $297.66
  • Analyst Decision
  • GH Strong Buy
  • PIPR Buy
  • Analyst Count
  • GH 14
  • PIPR 3
  • Target Price
  • GH $39.93
  • PIPR $193.00
  • AVG Volume (30 Days)
  • GH 1.6M
  • PIPR 102.3K
  • Earning Date
  • GH 11-06-2024
  • PIPR 01-31-2025
  • Dividend Yield
  • GH N/A
  • PIPR 0.87%
  • EPS Growth
  • GH N/A
  • PIPR 122.99
  • EPS
  • GH N/A
  • PIPR 9.33
  • Revenue
  • GH $692,256,000.00
  • PIPR $1,513,658,000.00
  • Revenue This Year
  • GH $32.23
  • PIPR $13.28
  • Revenue Next Year
  • GH $16.90
  • PIPR $16.18
  • P/E Ratio
  • GH N/A
  • PIPR $31.91
  • Revenue Growth
  • GH 29.20
  • PIPR 19.45
  • 52 Week Low
  • GH $15.81
  • PIPR $162.50
  • 52 Week High
  • GH $38.53
  • PIPR $351.80
  • Technical
  • Relative Strength Index (RSI)
  • GH 45.64
  • PIPR 33.10
  • Support Level
  • GH $34.20
  • PIPR $321.45
  • Resistance Level
  • GH $36.24
  • PIPR $336.49
  • Average True Range (ATR)
  • GH 1.70
  • PIPR 9.04
  • MACD
  • GH -0.92
  • PIPR -5.36
  • Stochastic Oscillator
  • GH 15.98
  • PIPR 17.36

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About PIPR Piper Sandler Companies

Piper Sandler Cos is an investment banking company. Investment banking services include financial advisory services, management of and participation in underwriting, and public finance activities. It generates maximum revenue from Advisory services followed by Equity financing. The company focuses on the following sectors: healthcare; energy; consumer; diversified industrials and services; business services; technology; financial services; agriculture, clean technologies, and renewables, focusing on middle-market clients.

Share on Social Networks: